Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
China's National Financial Regulatory Administration is soliciting public comment on a draft revision of the PRC Insurance Law.
2026-09-04
China's National Financial Regulatory Administration is soliciting public comment on a draft revision of the PRC Insurance Law.
Back
Other News
2026-09-04
Thailand has suspended 49 data center projects after rising public concern over the facilities’ high power consumption and community impact. The National Economic and Social Development Council said the pause is to allow time to draft new industry re
Thailand has suspended 49 data center projects after rising public concern over the facilities’ high power consumption and community impact. The National Economic and Social Development Council said the pause is to allow time to draft new industry regulations, expected within a month. The finance minister said the decision is not a ban on investment, calling data centers critical to Thailand’s competitiveness while stressing the need for clear, unified standards to ensure sustainable development. The government will establish a unified regulatory mechanism to cover both operating and under-construction data centers.
2026-09-04
September 4 — Merck said China’s NMPA approved its PD‑1 inhibitor pembrolizumab for adults with resectable locally advanced head‑and‑neck squamous cell carcinoma whose tumors express PD‑L1 (combined positive score CPS ≥1) by a validated test. Approva
September 4 — Merck said China’s NMPA approved its PD‑1 inhibitor pembrolizumab for adults with resectable locally advanced head‑and‑neck squamous cell carcinoma whose tumors express PD‑L1 (combined positive score CPS ≥1) by a validated test. Approval covers single-agent neoadjuvant use, postoperative adjuvant radiotherapy with or without cisplatin, and continued pembrolizumab monotherapy thereafter.
Chat with us
, powered by
LiveChat